deltatrials
Completed PHASE2 INTERVENTIONAL 3-arm NCT03248531

A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.

A Phase 2 Multicenter, Investigator-Blind, Subject-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa

Sponsor: UCB Biopharma SRL

Conditions Hidradenitis Suppurativa
Interventions Adalimumab Bimekizumab Placebo
Updated 26 times since 2017 Last updated: Mar 14, 2022 Started: Sep 22, 2017 Primary completion: Nov 23, 2018 Completion: Feb 21, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03248531, this PHASE2 trial focuses on Hidradenitis Suppurativa and remains completed. Sponsored by UCB Biopharma SRL, it has been updated 26 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Sep 2017 – ~Nov 2017 · 2 months · monthly snapshot~Nov 2017 – ~Dec 2017 · 30 days · monthly snapshot~Dec 2017 – ~Jan 2018 · 31 days · monthly snapshot~Jan 2018 – ~Mar 2018 · 59 days · monthly snapshot~Mar 2018 – ~Apr 2018 · 31 days · monthly snapshot~Apr 2018 – ~May 2018 · 30 days · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Apr 2019 · 59 days · monthly snapshot~Apr 2019 – ~Jun 2019 · 2 months · monthly snapshot~Jun 2019 – ~Dec 2019 · 6 months · monthly snapshot~Dec 2019 – ~Apr 2020 · 4 months · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Mar 2022 · 14 months · monthly snapshot~Mar 2022 – ~May 2022 · 2 months · monthly snapshot~May 2022 – ~Jul 2024 · 26 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

26 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. May 2022 — Jul 2024 [monthly]

    Completed PHASE2

  5. Mar 2022 — May 2022 [monthly]

    Completed PHASE2

▶ Show 21 earlier versions

  1. Jan 2021 — Mar 2022 [monthly]

    Completed PHASE2

  2. Apr 2020 — Jan 2021 [monthly]

    Completed PHASE2

  3. Dec 2019 — Apr 2020 [monthly]

    Completed PHASE2

  4. Jun 2019 — Dec 2019 [monthly]

    Completed PHASE2

  5. Apr 2019 — Jun 2019 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  6. Feb 2019 — Apr 2019 [monthly]

    Active Not Recruiting PHASE2

  7. Jan 2019 — Feb 2019 [monthly]

    Active Not Recruiting PHASE2

  8. Dec 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE2

  9. Nov 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE2

  10. Oct 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE2

  11. Sep 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE2

  12. Aug 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE2

  13. Jul 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  14. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2

  15. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  16. Apr 2018 — May 2018 [monthly]

    Recruiting PHASE2

  17. Mar 2018 — Apr 2018 [monthly]

    Recruiting PHASE2

  18. Jan 2018 — Mar 2018 [monthly]

    Recruiting PHASE2

  19. Dec 2017 — Jan 2018 [monthly]

    Recruiting PHASE2

  20. Nov 2017 — Dec 2017 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  21. Sep 2017 — Nov 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • UCB Biopharma SRL
Data source: UCB Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Athens, Greece , Berlin, Germany , Bochum, Germany , Boston, United States , Brussels, Belgium , Chapel Hill, United States , Copenhagen, Denmark , Coral Gables, United States , Darmstadt, Germany , Dessau, Germany and 21 more locations